Lead Product(s): KNP-301
Therapeutic Area: Ophthalmology Product Name: KNP-301
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Kanaph Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 24, 2020
Samsung Biologics will provide a full scope of its CDO services from cell line development, process development, non-clinical and clinical material manufacturing to IND submission for KNP-301, a bi-specific Fc fusion protein intended to treat retinal diseases.